- Policy
- 'Will adjust the price of generic drugs through reevals'
- by Lee, Jeong-Hwan Oct 16, 2024 05:50am
- The Ministry of Health and Welfare responded to the NA’s inquiry on the ministry's policy operation plan to realize generic drug prices in Korea, explaining that the MOHW is promoting a plan to reduce and adjust drug prices through ‘external reference pricing re-evaluations.’ This means that the ministry will start the external referen
- Policy
- Amgen starts negotiations to extend reimb of Kyprolis
- by Lee, Tak-Sun Oct 15, 2024 05:50am
- The reimbursement extension process for the multiple myeloma drug Kyprolis (carfilzomib, Amgen) has entered the final stage. Its insurance drug price is being negotiated with the National Health Insurance Service. The discussion is likely for the use of Kyprolis in the Kyprolis+daratumumab+dexamethasone (DKd) regimen, which passed the Can
- Company
- oHCM drug Camzyos's last hurdle to reimb remains high
- by Eo, Yun-Ho Oct 15, 2024 05:50am
- The reimbursement journey for ‘Camzyos’, which is seeking insurance reimbursement in Korea, is going to be a rocky road until the end. According to industry sources, the drug pricing negotiations between BMS Pharmaceuticals Korea and the National Health Insurance Service (NHIS) for the obstructive hypertrophic cardiomyopathy (oHCM) drug
- Company
- “Market for veterinary drugs expected to grow rapidly”
- by Son, Hyung Min Oct 15, 2024 05:50am
- “MSD Animal Health Korea’s clients are animals. We believe that the drug distribution channels for animals should be carefully designed to contribute to the health of animals in Korea. Supplying our products to animals that need them quickly, sufficiently, and safely is the biggest principle in designing our domestic distribution network.
- Policy
- Reduced reimb for medicines-containing choline alfoscerate
- by Lee, Tak-Sun Oct 15, 2024 05:49am
- Complaints have been circulating regarding the decision made by the Health Insurance Review and Assessment Service (HIRA) to reduce reimbursement on medical care reimbursement claims for medicines containing 'choline alfoscerate,' a brain function-improving agent. Medicines-containing choline alfoscerate received selective reimbursement
- Policy
- Will generics dominate the oral psoriasis treatment market?
- by Lee, Tak-Sun Oct 14, 2024 05:49am
- The global market for oral psoriasis treatment amounts to KRW 5 trillion. In the Korean market, generic medicines are likely to dominate. The original medicine company withdrew its drug from the Korean market due to dissatisfaction with the reimbursement decision, whereas generic medicines are likely to accept the term. A new type of oral
- Policy
- NA-MFDS clash on the approval of abortion pills
- by Lee, Jeong-Hwan Oct 14, 2024 05:49am
- With the National Assembly strongly pressing the need for domestic marketing authorization of the abortion drug ‘Mifegymiso,’ the NA’s request is set to affect the future administration of the MFDS’s marketing authorization review. The MFDS has repeatedly argued that the Criminal Act and the Mother and Child Health Act must be amen
- Policy
- Approval process for 'Leqembi' heavily debated
- by Lee, Hye-Kyung Oct 14, 2024 05:49am
- A heated debate is expected during the National Assembly regarding the approval process for Leqembi (lecanemab), a new drug for treating dementia that received domestic approval in May. At a parliamentary audit of the Health and Welfare Committee held at the National Assembly on October 10th, Rep. Jeon Jin-sook, a member of the Democratic
- Policy
- Drug pricing negotiations for Qarziba gather pace
- by Lee, Tak-Sun Oct 14, 2024 05:49am
- With Qarziba Inj (dinutuximab beta, Recordati Korea), the first drug that has been applied the approval-evaluation-negotiation pilot project, passing the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee, the drug price negotiation for the drug is also expected to progress quickly. However, the drug
- Company
- Dong-A ST’s biosimilar first enters the U.S. market
- by Chon, Seung-Hyun Oct 14, 2024 05:49am
- Dong-A S.T. has succeeded in entering the US market 13 years after declaring its entry into the biosimilar business. It has received approval in the US for a biosimilar version of Stelara, which owns a global market worth KRW 14 trillion. It was the company’s second overseas market with a self-developed biosimilar. The biosimilar's entry into t
